Biomed Environ Sci, 2014; 27(4):

Size: px
Start display at page:

Download "Biomed Environ Sci, 2014; 27(4):"

Transcription

1 Biomed Environ Sci, 2014; 27(4): Original Article A Novel High Nitrogen Nickel-free Coronary Stents System: Evaluation in a Porcine Model ZHANG Bin, CHEN Ming #, ZHENG Bo, WANG Xin Gang, WANG Xi Ting, FAN Yuan Yuan, and HUO Yong Department of Cardiology of Peking University First Hospital, Beijing , China Abstract Objective To study the safety of the novel high nitrogen nickel-free austenitic stainless steel bare metal stents (BMS) in a recognized porcine coronary model and to select a better grid structure of it. Methods Three types of stents were randomly implanted in different coronary arteries of the same pig: 316L stainless steel BMS (316L-BMS) (n=12), novel high nitrogen nickel-free stents Grid A (NF-A-BMS) (n=12) and novel high nitrogen nickel-free stents Grid B (NF-B-BMS) (n=12). In total, eighteen animals underwent successful random placement of 36 oversized stents in the coronary arteries. Coronary angiography was performed after 36 d of stents implantation. Nine animals were respectively sacrificed after 14 d and 36 d for histomorphologic analysis. Results Quantitative coronary angiography (QCA) showed similar luminal loss (LL) in the three groups: (0.21±0.17) mm for 316L-BMS, (0.16±0.12) mm for NF-A-BMS, (0.24±0.15) mm for NF-B-BMS (P>0.05). Histomorphomeric analysis after 15 d and 36 d revealed that there was also no significant difference among the three groups in neointimal area (NA) with similar injury scores respectively. High magnification histomorphologic examination showed similar inflammation scores in the three groups, but NF-A-BMS group had poorer endothelialization scores compared with NF-B-BMS group, 2.00±0.63 vs. 2.83±0.41 (P=0.015) at 15 d, which also could be proved by the scanning electron microscope. However, the difference could not been observed at 36 d. Conclusion The novel NF-BMS showed similar safety as 316L-BMS during the short-term study. NF-B-BMS had better endothelialization than NF-A-BMS and this may owe to the specific strut units. Key words: Austenitic steel; Bare metal stent; Endothelialization; Restenosis; Stent thrombosis Biomed Environ Sci, 2014; 27(4): doi: /bes ISSN: (full text) CN: /Q Copyright 2014 by China CDC INTRODUCTION W ith the appearance of drug-eluting stents (DES), the restenosis rate of percutaneous coronary intervention (PCI) has dropped to below 10% [1] compared with 20%-30% of bare metal stents (BMS) generation [2]. However, with the increasing number of patients receiving intervention treatment, safety issue raised for long-term use of this technology. Stent restenosis (SR) and stent thrombosis (ST) are two of the most fatal problems unresolved. When the drug on the stent has been released completely, especially with the biodegradable coating on the new generation of DES also degraded gradually, there is only the metal stent platform retained in the blood vessel wall. # Correspondence should be addressed to CHEN Ming. Tel: cm6141@sina.com Biographical note of the first author: ZHANG Bin, male, born in 1983, PhD Candidate, majoring in cardiology intervention. Received: January 31, 2013; Accepted: July 9, 2013

2 290 Biomed Environ Sci, 2014; 27(4): Obviously, it is a major factor affecting the late event of blood vessels, which can t be ignored. As a main component of traditional stainless steel, nickel is a potential allergenic factor for the blood vessel wall, which may cause cytotoxicity and inflammation [3-4] and eventually result in SR or ST. Improving the components of the stent platform may therefore reduce the late adverse events. Cobalt alloy stents [5-6], and platinum alloy stents [7] have been developed in western countries and they showed excellent outcomes in the late events. Fortunately, novel metal material, high nitrogen nickel-free austenitic stainless steel (Institution of Metal Research, Chinese Academy of Sciences) with independent intellectual property rights, has been used on the platform of BMS. This study aims to analyze the safety of the novel high nitrogen nickel-free austenitic stainless steel BMS in a recognized porcine coronary model and also to select a better grid structure of it. Materials METHODS Stents All three types of stents were balloon-expandable BMS with the size of 3.0 mmx15 mm: commercial available 316L stainless steel BMS (316L-BMS) (SINO Medical Sciences and Technology INC, China), novel high nitrogen nickel-free stents Grid A (NF-A-BMS) and novel high nitrogen nickel-free stents Grid B (NF-B-BMS). Animal The animal study was approved by the Institutional Animal Care and Use Committee of Peking University First Hospital and conformed to the Guide for the Care and Use of Laboratory Animals in Beijing. Eighteen Chinese Miniature Swine (30 kg to 55 kg and six months to eight months) purchased from China Agricultural University, China. The gender of the animals was ignored and they were fed a standard laboratory chow diet without lipid. Procedure A total of twelve 316L-BMS, thirteen NF-A-BMS and thirteen NF-B-BMS were randomly assigned and placed in the left anterior descending (LAD), circumflex (LCX), or right coronary artery (RCA) (two types of stents per two arteries of one pig). In order to decrease the incidence of acute thrombosis, premedication with 300 mg aspirin (Bayer, Germany) and 75 mg clopidogrel (Xin Li Tai Pharmaceutical Co. Ltd, China) was administered before stent implantation for one day. Aspirin (100 mg/d) and clopidogrel (75 mg/d) were then given until sacrificed. Subcutaneous injection of 0.3 mg/kg ketamine (Double-Crane Pharmaceutical Company, China) was administered to all pigs prior operation for basic anesthesia, and then intravenous injection of 0.05 g/l sodium pentobarbital (Peking University First Hospital Animal Center, China) was given to keep the status of anesthesia and to extend the experimental time. Onwards, the groin of the pig was fixed and sterilized, and the femoral artery was punctured with Seldinger method. Then, 6F sheath was inserted with intravenous injection of heparin (100 U/kg). With inch guide wire, 6F JL 3.5 and JR 3.5 guiding catheters were used for coronary angiography. According to the target vessel diameter, the stent size was selected (stent expanded diameter: vascular diameter, 1.1:1-1.2:1). Guide wire (0.014 inch) was sent to the distal coronary artery. Along the guide wire, the stent was pushed to the target vessel site and released by using 8 atm-12 atm single expansion for 5 s-10 s. The angiography was repeated to make sure that no serious dissection and thrombosis occurred. Then the sheath tube was withdrawn, and the puncture site was compressed to stop bleeding for 20 min-30 min, with intramuscular injection of U/kg penicillin for preventing infection. Quantitative Coronary Analysis (QCA) Evaluation At 36 d of implantation, operation for repeat coronary angiography on 9 animals was performed. QCA was performed by CAAS 5.9 QCA Software (PIE MEDICAL IMAGINE, Netherlands). Coronary artery measurements including baseline vessel diameter, minimal lumen diameter immediately after implantation (I-MLD), reference vessel diameter (RVD), MLD of repeat angiography (R-MLD) and lumen loss (LL) were recorded. Histopathological Evaluation At 15 d and 36 d of implantation, 9 animals were sacrificed one after another. The heart was removed and perfused with heparin saline for 5 min at the pressure of 100 mmhg (1 mmhg= kpa). The stent vessel segment was separated rapidly and fixed with 10% formaldehyde solution. The segments were embedded in methy methacrylate plastic for histological examination. The samples with stent were embedded by methyl methacrylate (Prepared by Peking University School of Stomatology), and

3 Biomed Environ Sci, 2014; 27(4): sliced (50 μm) with a hard tissue microtome (LEICA, Germany). All sections were stained with hematoxylin-eosin (HE), and specimens were prepared for light microscopy examination. Optical microscope (LEICA, Germany) and Qwin PLUS V3.2.1 image analysis software (LEICA, Germany) were used to measure lumen area (LA), internal elastic lamina area (IELA), external elastic lamina area (EELA), neointimal area (NA) (internal elastic lamina area - lumen area), and percent area stenosis (PAS) [(internal elastic lamina area-lumen area) / lumen area 100%]. Vascular injury score was determined by the method of Schwartz et al. (0=intact internal elastic lamina; 1=internal elastic lamina fracture; 2=internal elastic lamina and tunica media fracture; 3=external elastic plate fracture) [8]. Inflammation score was graded according to the inflammatory cells (0=no inflammatory cells; 1=scattered inflammatory cells; 2=inflammatory cells encompassing 50% of a strut in at least 25%-50% of the circumference of the artery; 3=inflammatory cells surrounding a strut in at least 25%-50% of the circumference of the artery) [9]. Stent endothelialization score was defined as the extent of the circumference of the arterial lumen covered by the endothelial cells and graded from 1 to 3 (1=0-25%, 2=25%-75%, 3=75%-100%) [10]. Statistical Analysis eighteen pigs (Table 1). All of the animals (100%) survived in the intended study interval with on angiographic stent thrombosis or other clinical complications. The body weight and abnormal body temperature of the animals remained well throughout the study. Quantitative image analysis of coronary angiography was showed in Figure 1 and Table 2. In the case of similar RVD and I-MLD among the three groups at baseline (P>0.05), there were no significant differences in R-MLD and LL statistically among the three groups (P>0.05). Results from pathology analysis were showed in Table 3. NA-one of the most crucial parameters on the stent efficiency evaluation was measured according to the histopathological photomicrographs (20x) of the stented coronary artery (Figure 2A-F). As shown in Figure 2G, the NA was not significantly different statistically among the three stent groups at 15 d and 36 d of implantation (P>0.05). Inflammation score and endothelialization score were Table 1. Status of Stent Implantation Type Number LAD LCX RCA 316L-BMS NF-A-BMS NF-B-BMS Total Values in normal distribution were expressed as mean±standard deviation (SD). Group imaging, histological and integral data were analyzed with one-way ANOVA test. n representing the number of stents of different types. The value of P<0.05 was considered statistically significant. All statistical analysis were performed by commercially available SPSS 14.0 system software (IBM, USA). RESULTS A total of 36 stents of three types were successfully implanted in coronary arteries of Figure d Lumen Loss in Different Groups. Table 2. QCA Results at 36 d of Stent Implantation QCA Results 316L-BMS (n=6) NF-A-BMS (n=6) NF-B-BMS (n=6) F P-value RVD (mm) 2.59± ± ± I-MLD (mm) 2.58± ± ± R-MLD (mm) 2.37± ± ± LL (mm) 0.21± ± ± Note. RVD, reference vessel diameter; I-MLD, minimal lumen diameter immediately after implantation; R-MLD, minimal lumen diameter of repeat angiography; LL, lumen loss.

4

5 Biomed Environ Sci, 2014; 27(4): Figure d and 36 d histopathological photomicrographs (20x) of stented coronary artery and neointimal areas in different groups. (A), 316L-BMS group at 15 d (20X); (B), NF-A-BMS group at 15 d (20X); (C), NF-B-BMS group at 15 d (20X); (D), 316L-BMS group at 36 d (20X); (E), NF-A-BMS group at 36 d (20X); (F), NF-B-BMS group at 36 d (20X); (G), Efficiency of the stents is determined by neointimal areas. Each column represents the mean±sd in different groups and end points. Figure 3. Histopathological photomicrographs (200x) of stented coronary artery, inflammation scores and endothelialization scores of 15 d and 36 d in different groups. (A), 316L-BMS group at 15 d (200X); (B), NF-A-BMS group at 15 d (200X); (C), NF-B-BMS group at 15 d (200X); (D), 316L-BMS group at 36 d (200X); (E), NF-A-BMS group at 36 d (200X); (F), NF-B-BMS group at 36 d (200X); (G-H), Safety of the stents is determined by inflammation score and endothelialization score. Each column represents the mean±sd in different groups and end points.

6 294 Biomed Environ Sci, 2014; 27(4): REFERENCES Figure d Scanning Electron Microscope. (A), NF-A-BMS group at 15 d; (B), NF-B-BMS group at 15 d. Endothelialization is the key point of ST mechanism [15]. Although vascular repairing in pigs occurs more rapidly than humans, the endothelialization score and the results from scanning electron microscope are also two available indexes in the model. In our present study, NF-A-BMS with two different strut units showed lower endothelialization score and poorer endothelialization under scanning electron microscope compared with NF-B-BMS consisting of the single strut unit within 15 d of implantation, but this difference did not extend to 36 d of implantation. There were no significant differences between the two types of NF-BMS and 316L-BMS in terms of the two endpoints. It suggests that the single strut unit design of NF-B-BMS may be a better choice for endothelialization and ST prevention. However, the conclusion can t be made until longer endpoint observation and further study is therefore needed to be carried out. Owing to the SR, ST and neoatherosclerosis [16] may occur much later in patients with stent implantation, the duration of this study is too short to evaluate long term safety, and it is one of the major limitations of our present study. Further preclinical study including long term endpoints and clinical study should be conducted in order to evaluate the safety and effectiveness of the novel NF-BMS. 1. Roiron C, Sanchez P, Bouzamondo A, et al. Drug-eluting stents: an updated meta-analysis of randomised controlled trials. Heart, 2006; 92, Fattori R and Piva T. Drug-eluting stents in vascular intervention. Lancet, 2003; 361, Coogan TP, Latta DM, Snow ET, et al. Toxicity and carcinogenicity of nickel compounds. Crit Rev Toxicol, 1989; 19, Uter W, Pfahlberg A, Gefeller O, et al. Risk factors for contact allergy to nickel - results of a multifactorial analysis. Contact Dermatitis, 2003; 48, Silber S, Windecker S, Vranckx P, et al. Unrestricted randomised use of two new generation drug-elutingcoronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet, 2011; 377, Claessen BE, Caixeta A, Henriques JP, et al. Current status of the Xience V everolimus-eluting coronary stent system. Expert Rev Cardiovasc Ther, 2010; 8, Kereiakes DJ, Cannon LA, Feldman RL, et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. J Am Coll Cardiol, 2010; 56, Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol, 1992; 19, Mehmet C, Jim E, Devang P, et al. Long-Term Effects of Novel Biolimus Eluting DEVAXAXXESS Plus Nitinol Self-Expanding Stent in a Porcine Coronary Model. Catheterization and Cardiovascular Interventions, 2006; 68, Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res, 2004; 63, Denkhaus E and Salnikow K. Nickel essentiality, toxicity, and carcinogenicity. Crit Rev Oncol Hematol, 2002; 42, Köster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet, 2000; 356, Yang K and Ren YB. Nickel-free austenitic stainless steels for medical applications. Sci Technol Adv Mater, 2010; 11, Ren YB, Yang K and Zhang BC. In vitro study of platelet adhesion on medical nickel-free stainless steel surface. Mater. Lett, 2005; 59, Stephan W and Bernhard M. Late Coronary Stent Thrombosis. Circulation, 2007; 116, Park SJ, Kang SJ, Virmani R, et al. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol, 2012, 59,

SKG Congress, 2015 EVOLVE II. Stephan Windecker

SKG Congress, 2015 EVOLVE II. Stephan Windecker SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,

More information

Catch-up Phenomenon: Insights from Pathology

Catch-up Phenomenon: Insights from Pathology Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re

More information

Run-Lin Gao, MD, FACC. On Behalf of I-LOVE-IT Trial Investigators

Run-Lin Gao, MD, FACC. On Behalf of I-LOVE-IT Trial Investigators I-LOVE-IT A Prospective, Multicenter Clinical Trial of TIVOLI Bioabsorbable Polymer Based Sirolimus-Eluting vs. ENDEAVOR Zotarolimus- Eluting Stent in Patients with Coronary Artery Disease: 8-Month Angiographic

More information

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research The Cardiovascular

More information

eluting Stents The SPIRIT Trials

eluting Stents The SPIRIT Trials Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus

More information

Stents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.

Stents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved. Stents selection and optimal implantation: sizes, design, deployment Stent classification: Mechanism of expansion - Self-expanding - Balloon expandable Design - Mesh structure - Coil - Slotted tube - Ring

More information

INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...

INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT... May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...

More information

Biodegradable Stents An update and work-in

Biodegradable Stents An update and work-in Biodegradable Stents An update and work-in in-progress Department of Cardiology, Hideo Tamai, M.D. Metallic stents... Background induce a varing degree of thrombogenesis eg, subacute thrombosis in complex

More information

Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial

Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan

More information

Development Of DES Technology. HUO Yong,MD FACC Peking University First Hospital President-elect Chinese Society of Cardiology

Development Of DES Technology. HUO Yong,MD FACC Peking University First Hospital President-elect Chinese Society of Cardiology Development Of DES Technology HUO Yong,MD FACC Peking University First Hospital President-elect Chinese Society of Cardiology Drug stents made in China Microport: Lepu: JW: Yinyi : Sinomed Yisheng Firebird

More information

Polymer-Free Stent CX - ISAR

Polymer-Free Stent CX - ISAR Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm

More information

Element Clinical Program Perseus Late Breaking News and the Platinum Study Design

Element Clinical Program Perseus Late Breaking News and the Platinum Study Design Element Clinical Program Perseus Late Breaking News and the Platinum Study Design Ian T. Meredith MBBS, BSc(Hons), Ph.D, FRACP, FACC, FCSANZ, FSCAI, FAHA, FAPSIC Professor and Director of Monash HEART

More information

Tailored bifurcation therapy

Tailored bifurcation therapy Tailored bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation lesion coverage without creating a false carina Bifurcation DES technology

More information

PCI for Left Anterior Descending Artery Ostial Stenosis

PCI for Left Anterior Descending Artery Ostial Stenosis PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary

More information

Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες

Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)

More information

PCI for Long Coronary Lesion

PCI for Long Coronary Lesion PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2

More information

Vascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts

Vascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts Vascular Intervention // Coronary Drug-Eluting Stent System Clinically proven Highly deliverable Ultrathin 60 μm struts The new benchmark for DES BIOFLOW-V 12-month clinical outcomes compared to Xience

More information

Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent

Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent implantation. Department of Cardiology, Ehime Prefectural Imabari

More information

Second Generation Drug Eluting Stents: From Inhibition to Healing

Second Generation Drug Eluting Stents: From Inhibition to Healing Second Generation Drug Eluting Stents: From Inhibition to Healing Mitchell W. Krucoff MD, FACC Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke

More information

Angiographic long-term results after implantation of the paclitaxel-eluting coronary stent coroflex please : Data under real-world conditions

Angiographic long-term results after implantation of the paclitaxel-eluting coronary stent coroflex please : Data under real-world conditions 244 U. Gerk, B. Leithäuser, U. Schäfer, F. Jung, J.-W. Park Applied Cardiopulmonary Pathophysiology 14: 244-249, 2010 Angiographic long-term results after implantation of the paclitaxel-eluting coronary

More information

Abstract Background: Methods: Results: Conclusions:

Abstract Background: Methods: Results: Conclusions: Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li

More information

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991

More information

Nobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy

Nobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life

More information

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES. A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.

More information

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal? HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic

More information

BIOFREEDOM: Polymer free Biolimus A9 eluting

BIOFREEDOM: Polymer free Biolimus A9 eluting TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,

More information

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research

More information

III. Results and Discussion

III. Results and Discussion III. Results and Discussion 1. Histological findings in the coronary artery Twenty-four swine had surgical treatments performed in two of the coronary arteries, LAD as well as either the LCX or RCA. A

More information

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center 2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular

More information

Yukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up

Yukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up Sirolimus Eluting CoCr Coronary Stent System Yukon Chrome PC 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts Yukon Chrome PC DES coating with excellent long-term

More information

IN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014

IN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014 IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological

More information

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the

More information

Complex PCI. Your partner in complex PCI: In-stent restenosis (ISR)

Complex PCI. Your partner in complex PCI: In-stent restenosis (ISR) Comple PCI Your partner in comple PCI: Your partner in comple PCI: Philips provides a portfolio of specialty coronary diagnostic and therapy devices that enable safe and effective treatment of a wide variety

More information

The titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath

The titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath The titanium nitride oxide stent an alternative to DES Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath Advanced Angioplasty 2008 Declaration of interest I have received an honorarium

More information

A Case of Recoiling of Everolimus - eluting Stent at the Ostium of the Right Coronary Artery by Out - stent Plaque Progression

A Case of Recoiling of Everolimus - eluting Stent at the Ostium of the Right Coronary Artery by Out - stent Plaque Progression Jikeikai Med J 2016 ; 63 : 71-6 Case Report A Case of Recoiling of Everolimus - eluting Stent at the Ostium of the Right Coronary Artery by Out - stent Plaque Progression Haruka Kimura, Tetsuya Ishikawa,

More information

Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition

Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J

More information

UNDERSTANDING TREATMENT OPTIONS FOR HEART DISEASE. Visit

UNDERSTANDING TREATMENT OPTIONS FOR HEART DISEASE. Visit Visit www.absorbstent.com UNDERSTANDING TREATMENT OPTIONS FOR HEART DISEASE UNDERSTANDING YOUR BLOCKED ARTERIES CORONARY ARTERY DISEASE MAY BE AFFECTING YOU OR SOMEONE YOU LOVE. Your heart needs a constant

More information

Histopathological Analysis of Drug Eluting Stents in Porcine Coronary Restenosis Model

Histopathological Analysis of Drug Eluting Stents in Porcine Coronary Restenosis Model Biomaterials Research (2013) 17(2) : 062-066 Biomaterials Research C The Korean Society for Biomaterials Histopathological Analysis of Drug Eluting Stents in Porcine Coronary Restenosis Model Kyung Seob

More information

Smooth muscle pharmacology & interventional cardiology

Smooth muscle pharmacology & interventional cardiology Smooth muscle pharmacology & interventional cardiology By: Pascal Bernatchez!!!!! LAST LECTURE Classic Vascular pharmacology -chronic -systemic Local Vascular pharmacology -acute -targeted High blood pressure

More information

Drug Eluting Stents: Bifurcation and Left Main Approach

Drug Eluting Stents: Bifurcation and Left Main Approach TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS

More information

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:

More information

Taking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe

Taking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows

More information

The BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino

The BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide

More information

Assurant Cobalt Iliac BALLOON EXPANDABLE STENT SYSTEM

Assurant Cobalt Iliac BALLOON EXPANDABLE STENT SYSTEM Assurant Cobalt Iliac BALLOON EXPANDABLE STENT SYSTEM Innovating for life. CONFORMABILIT Y 6 F S H E AT H C O M PAT I B I L I T Y THE ASSURANT COBALT ILIAC STENT, WITH ITS UNIQUE COBALT CHROMIUM MODULAR

More information

PROMUS Element Experience In AMC

PROMUS Element Experience In AMC Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical

More information

What Stent to Use? JASVINDAR SINGH MD, FACC

What Stent to Use? JASVINDAR SINGH MD, FACC What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar

More information

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on

More information

Review Report. Instrument & Apparatus 7 Organ function replacement device

Review Report. Instrument & Apparatus 7 Organ function replacement device Review Report February 6, 2009 Pharmaceuticals and Medical Devices Agency The results of a regulatory review conducted by the Pharmaceuticals and Medical Devices Agency on the following medical device

More information

DESolve NX Trial Clinical and Imaging Results

DESolve NX Trial Clinical and Imaging Results DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or

More information

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi

More information

Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions

Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large

More information

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement

More information

The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio

The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have

More information

Clinical Investigations

Clinical Investigations Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen

More information

C. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller

C. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,

More information

Disclosure Eberhard Grube, M.D.

Disclosure Eberhard Grube, M.D. Disclosure Eberhard Grube, M.D. I disclose the following financial relationships: Consultant Sadra Medical, Core Valve, Biosensors, Orbus Neich, Cordis Johnson & Johnson, Boston Scientific, Mitralign,

More information

ABT 578 Elution from Phosphorylcholine: Zomaxx (Abbott)

ABT 578 Elution from Phosphorylcholine: Zomaxx (Abbott) ABT 578 Elution from Phosphorylcholine: Zomaxx (Abbott) Alan Yeung, MD Professor of Medicine, Interventional Cardiology Chair, Chief, Division of Cardiovascular Medicine (Clinical) Stanford University

More information

Journal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.

Journal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30. Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009

More information

Boston Scientific Corporation Drug-Eluting Stent Program

Boston Scientific Corporation Drug-Eluting Stent Program Boston Scientific Corporation Drug-Eluting Stent Program Copyright 2002 by Scimed Life Systems, Inc. All rights reserved. Program Overview λ λ λ λ λ World Wide Status Restenosis Paclitaxel Polymers Dose

More information

Drug eluting stents (DES) have decreased

Drug eluting stents (DES) have decreased JACC: CARDIOVASCULAR IMAGING VOL. 5, NO. 11, 1 1 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36. PUBLISHED BY ELSEVIER INC. http://dx.doi.org/1.116/j.jcmg.1.. BRIEF REPORT OCT-Verified

More information

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators

More information

Bioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals

Bioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for

More information

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.

More information

Neuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology

Neuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology Eberhard-Karls Karls-University of Tubingen Department of Diagnostic Radiology Neuestes aus der Therapie der pavk Berlin Dezember 08 beschichtete Stents + Ballons Gunnar Tepe 1 Local Drug Delivery Basic

More information

Coronary Stent Choice in Patients With Diabetes Mellitus

Coronary Stent Choice in Patients With Diabetes Mellitus Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University

More information

Zotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China

Zotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 7, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2013.03.001

More information

Bioresorbable polymer drug-eluting stents in PCI

Bioresorbable polymer drug-eluting stents in PCI EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed

More information

Non stent based intracoronary drug delivery

Non stent based intracoronary drug delivery Non stent based intracoronary drug delivery Dariusz Dudek Department of Interventional Cardiology Jagiellonian University, Krakow, Poland The European Association of Percutaneous Cardiovascular Interventions

More information

Vessel healings after stenting with different polymers in STEMI patients

Vessel healings after stenting with different polymers in STEMI patients Journal of Geriatric Cardiology (2016) 13: 306 311 2016 JGC All rights reserved; www.jgc301.com Research Article Open Access Vessel healings after stenting with different polymers in STEMI patients Qin-Hua

More information

Frequency of Vascular Inflammation and Impact on Neointimal Proliferation of Drug Eluting Stents in Porcine Coronary Arteries

Frequency of Vascular Inflammation and Impact on Neointimal Proliferation of Drug Eluting Stents in Porcine Coronary Arteries Original Article Acta Cardiol Sin 2016;32:570 577 doi: 10.6515/ACS20151013G Atherosclerosis Frequency of Vascular Inflammation and Impact on Neointimal Proliferation of Drug Eluting Stents in Porcine Coronary

More information

SeQuent Please World Wide Registry

SeQuent Please World Wide Registry Journal of the American College of Cardiology Vol. 6, No. 18, 212 212 by the American College of Cardiology Foundation ISSN 735-197/$36. Published by Elsevier Inc. http://dx.doi.org/1.116/j.jacc.212.7.4

More information

DRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.

DRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are

More information

Sirolimus-Eluting Stents for Treatment of In-Stent Restenosis

Sirolimus-Eluting Stents for Treatment of In-Stent Restenosis Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique

More information

Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results

Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results Stefan Verheye, MD PHD ZNA Middelheim Antwerp, Belgium Potential

More information

Prevention of Coronary Stent Thrombosis and Restenosis

Prevention of Coronary Stent Thrombosis and Restenosis Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary

More information

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main

More information

Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance

Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance Richard Kuntz Brigham and Women s s Hospital Harvard Medical School Late Loss and DES Brief history of Late Loss

More information

PCI for In-Stent Restenosis. CardioVascular Research Foundation

PCI for In-Stent Restenosis. CardioVascular Research Foundation PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse

More information

Optical Coherence Tomography for Intracoronary Imaging

Optical Coherence Tomography for Intracoronary Imaging Optical Coherence Tomography for Intracoronary Imaging Lorenz Räber Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

More information

Biosensors Lunch Symposium

Biosensors Lunch Symposium Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM

More information

CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer

CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time

More information

Conflict of interest :None. Meta-analysis. Zhangwei Chen, MD

Conflict of interest :None. Meta-analysis. Zhangwei Chen, MD Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,

More information

Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ

Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ DES Penetration -(2011) Source: Millenium Research Group Cordis has stopped manufacturing

More information

Stent Fracture and Longitudinal Compression on CT Angiography between the

Stent Fracture and Longitudinal Compression on CT Angiography between the 2014 ASCI Stent Fracture and Longitudinal Compression on CT Angiography between the First- and New-Generation Drug-Eluting Stent Mi Sun Chung, Dong Hyun Yang,Young-Hak Kim, Jae-Hyung Roh, Joon-Won Kang,

More information

INSIDE INFORMATION YOU CAN T IGNORE

INSIDE INFORMATION YOU CAN T IGNORE INSIDE INFORMATION YOU CAN T IGNORE Volcano, the Volcano logo and SyncVision are registered trademarks of Volcano Corporation. All other trademarks set-forth are properties of their respective owners.

More information

OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT

OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT Substudy Carlo Di Mario, MD Peter Barlis, MD Evelyn Regar, MD Peter Juni, MD Patrick

More information

Solving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System

Solving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System Volume 1, Issue 1 Case Report Solving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System Robert F. Riley * and Bill Lombardi University of Washington Medical Center, Division

More information

Bifurcations Bad Krozingen I

Bifurcations Bad Krozingen I Bifurcations Bad Krozingen I Clinical outcome 5 years after routine T-Stenting versus provisional T-stenting in the treatment of de novo coronary bifurcation lesions using sirolimus-eluting stents M. Ferenc

More information

Yukon Choice PC Translumina trust is what counts

Yukon Choice PC Translumina trust is what counts Sirolimus Eluting Coronary Stent System 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts DES with excellent long-term clinical outcome The Translumina PC drug-eluting

More information

LM stenting - Cypher

LM stenting - Cypher LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with

More information

Coroflex ISAR. Sirolimus Eluting Polymer-Free Coronary Stent System. Vascular Systems

Coroflex ISAR. Sirolimus Eluting Polymer-Free Coronary Stent System. Vascular Systems Coroflex ISAR Sirolimus Eluting Polymer-Free Coronary Stent System Vascular Systems Coroflex ISAR Polymer-Free Drug Coating Complete Drug Release Sirolimus Established anti-inflammatory and anti-proliferative

More information

Eighteen-month outcome of pulmonary valve stent implantation by direct right ventricle puncture: An animal study

Eighteen-month outcome of pulmonary valve stent implantation by direct right ventricle puncture: An animal study Eighteen-month outcome of pulmonary valve stent implantation by direct right ventricle puncture: An animal study Gang-Jun Zong, MD, PhD, a Yuan Bai, MD, b Ming-Biao Gu, MD, b Hai-Bin Jiang, MD, b Hong

More information

Chinese Medical Journal 2013;126 (6) 1027 independent predictor of negative prognostic outcome, in terms of restenosis, after DES implementation. 7,8

Chinese Medical Journal 2013;126 (6) 1027 independent predictor of negative prognostic outcome, in terms of restenosis, after DES implementation. 7,8 1026 Original article Efficacy and safety of FIREHAWK abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: nine-month angiographic and one-year

More information

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,

More information

in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore

in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore Unrelenting Left Main Disease in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore Clinical History 72 years old Chinese lady Background and CV Risk

More information

The tailored solution for your bifurcation therapy

The tailored solution for your bifurcation therapy The tailored solution for your bifurcation therapy The tailored solution for your bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation

More information

Relationship between Angiographic Late Loss and 5-Year Clinical Outcome after Drug-Eluting Stent Implantation

Relationship between Angiographic Late Loss and 5-Year Clinical Outcome after Drug-Eluting Stent Implantation Original Article http://dx.doi.org/10.3349/ymj.2013.54.1.41 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 54(1):41-47, 2013 Relationship between Angiographic Late Loss and 5-Year Clinical Outcome after

More information

Longitudinal compression of the cobalt-chromium. everolimus-eluting stent during Percutaneous Coronary

Longitudinal compression of the cobalt-chromium. everolimus-eluting stent during Percutaneous Coronary Longitudinal compression of the cobalt-chromium everolimus-eluting stent during Percutaneous Coronary Implantation: The first report of accordion effect in Xience prime family in vivo LI CG 1, Dai YX 1,

More information

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.

More information